SHR-1918

Monoclonal antibody

Filedunder review

Evidence outlook · regulatory review

Homozygous Familial Hypercholesterolemia: application under NMPA review

NMPA accepts the SHR-1918 marketing application in HoFH, with priority review (2026-02-24). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

NCT06723652: This is a randomized, quadruple-blinded, placebo-controlled trial with a disease-defining efficacy endpoint (percent change in LDL cholesterol), but results have not been posted, so whether SHR-1918 lowered LDL cholesterol significantly versus placebo cannot yet be confirmed from this record.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Homozygous Familial Hypercholesterolemia
Other / comorbidity
NCT07230730 · Beijing Suncadia Pharmaceuticals Co., Ltd
2026-01-13 – 2027-10 · Hyperlipidemia
What this study did
NCT07349615 · Beijing Suncadia Pharmaceuticals Co., Ltd
2026-03-31 – 2027-10 · Hypertriglyceridemia
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT07404553 · Beijing Suncadia Pharmaceuticals Co., Ltd
2026-04-30 – 2028-08 · Hypercholesterolemia
What this study did
Phase 2 (5)
Homozygous Familial Hypercholesterolemia
NCT07133815 · Beijing Suncadia Pharmaceuticals Co., Ltd
2025-08 – 2027-12 · Homozygous Familial Hypercholesterolemia
What this study did
Other / comorbidity
NCT07308392 · Fujian Shengdi Pharmaceutical Co., Ltd.
2026-02-25 – 2027-06 · Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
What this study did
NCT06109831 · Beijing Suncadia Pharmaceuticals Co., Ltd
2023-11-24 – 2025-07-04 · Hyperlipidemic
What this study did
NCT06471218 · Beijing Suncadia Pharmaceuticals Co., Ltd
2024-07-02 – 2025-05-16 · Hyperlipidemia
What this study did
Phase 1 (1)
Other / comorbidity
NCT05432544 · Beijing Suncadia Pharmaceuticals Co., Ltd
2022-06-27 – 2023-12-12 · Hyperlipemia
What this study did

Competitive landscape

This mechanism is crowded: 9 other tracked programmes target it, 1 of them ahead of this one.

This drug's own stage for Homozygous Familial Hypercholesterolemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SHR-1918: this drugPhase 3Monoclonal antibodyANGPTL3Partial signal
NCT06723652: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT03156621: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3)
Evinacumab (Evkeeza)ApprovedMonoclonal antibodyANGPTL3Partial signal
NCT03399786: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5)
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Reliable signal
NCT01588496: Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001
Ezetimibe (Zetia)ApprovedSmall moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Inclisiran (Leqvio)ApprovedRNA / oligonucleotidePCSK9Partial signal
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
Lomitapide (Juxtapid)ApprovedSmall moleculeMTPWeak signal
NCT04681170: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658)
NCT02173158: Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16)
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
ZodasiranPhase 3RNA / oligonucleotideANGPTL3 gene mRNA (hepatic)not yet gradedNo reviewed efficacy summary in this indication
ALN-ANG3
Phase 2(overall)
RNA / oligonucleotideANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication
BW-00112
Phase 2(overall)
RNA / oligonucleotideANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication
EDP167
Phase 2(overall)
RNA / oligonucleotideANGPTL3
Weak signal(overall)
No reviewed efficacy summary in this indication
Solbinsiran
Phase 2(overall)
RNA / oligonucleotideANGPTL3
Partial signal(overall)
No reviewed efficacy summary in this indication
SYH2070
Phase 2(overall)
RNA / oligonucleotideANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication
CTX310
Phase 1(overall)
Gene therapy / editingANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication
NNC0491-6075
Phase 1(overall)
Monoclonal antibodyANGPTL3
Weak signal(overall)
No reviewed efficacy summary in this indication
AZD1705
Discontinued
RNA / oligonucleotideANGPTL3
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SHR-1918 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
March 2027 (1)
Phase 3HypertriglyceridemiaActive not recruiting
Est. primary completion 2027-03 · NCT07349615 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisActive not recruiting
Est. primary completion 2027-06 · NCT07308392 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3HyperlipidemiaRecruiting
Est. primary completion 2027-10 · NCT07230730 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Phase 2/3HypercholesterolemiaRecruiting
Est. primary completion 2028-07 · NCT07404553 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026Topline resultPhase 3 (NCT06723652) presented at ESC 2026: LDL-C 64.2% lower than placebo at week 12
24 February 2026Filing acceptedNMPA accepts the SHR-1918 marketing application in HoFH, with priority review
CN, NMPA · Beijing Suncadia Pharmaceuticals (Hengrui subsidiary) · Source ↗